The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...

First-line ORR was 54.8% with Dato-DXd/pembrolizumab and 55.6% with added platinum, indicating substantial activity without mandatory chemotherapy. Durability and time-to-event outcomes favored the ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

This is part 4 of an interview. Watch part 1, part 2, and part 3.

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

CHIMERA enrolls surgical candidates with stage I–IIIa epithelioid or biphasic pleural mesothelioma, aiming to optimize multimodality outcomes in a highly selected population. Treatment includes ...

CLARITY-Gastric01 met dual OS primary end points, showing statistically significant, clinically meaningful benefit for Sone‑Ve over chemotherapy in third-line+ and overall second-line+ cohorts.

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, ...

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

In an interview with Targeted OncologyTM, Ranjit Goudar, MD, of Virginia Oncology Associates, discusses the ongoing barriers ...

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...